Overview Dividends

(RGEN) Repligen - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US7599161095

Protein A Ligands, Chromatography Columns, Filtration Systems, Process Analytics

RGEN EPS (Earnings per Share)

EPS Growth (3Y CAGR): -13.25%
EPS Trend (3Y Correlation): -37.2%

RGEN Revenue

Revenue Growth (3Y CAGR): 0.40%
Revenue Trend (3Y Correlation): 18.4%

Risk via 10d forecast
Volatility	48.2%
Value at Risk 5%th	71.2%

Reward
Sharpe Ratio	0.42
Alpha Jensen	-4.79

Character
Hurst Exponent	0.385
Beta	1.128

Drawdowns 3y
Max DD	47.75%
Mean DD	23.92%

Description: RGEN Repligen November 04, 2025

Repligen Corporation (NASDAQ:RGEN) is a life-sciences firm that designs, manufactures, and sells bioprocessing technologies and systems across North America, Europe, and the Asia-Pacific. Its product portfolio includes Protein A affinity ligands, cell-culture growth factors, OPUS pre-packed and small-scale chromatography columns, filtration devices such as XCell ATF and TangenX cassettes, and process-analytics tools under the SoloVPE/FlowVPE brands. Customers span biopharma, diagnostics, academic labs, and contract manufacturing organizations, and the company maintains a partnership with Navigo Proteins GmbH to co-develop new affinity ligands.

Key recent metrics: FY 2023 revenue reached approximately $1.0 billion, with a gross margin near 70% and recurring consumable sales accounting for roughly 55% of total revenue-a sign of stable, repeatable demand. The bioprocessing market is being driven by a surge in biologics pipelines (projected CAGR ≈ 10% through 2028) and the shift toward single-use, high-throughput platforms that favor Repligen’s chromatography and filtration solutions. Additionally, the company’s cash conversion cycle has shortened to under 45 days, reflecting efficient working-capital management.

For a deeper quantitative dive, the ValueRay platform offers a granular breakdown of RGEN’s financial and operational metrics.

RGEN Stock Overview

Market Cap in USD	8,039m
Sub-Industry	Life Sciences Tools & Services
IPO / Inception	1990-03-26
Return 12m vs S&P 500	-8.23%
Analyst Rating	4.26 of 5

RGEN Dividends

Currently no dividends paid

RGEN Growth Ratios

CAGR	-6.18%
CAGR/Max DD Calmar Ratio	-0.13
CAGR/Mean DD Pain Ratio	-0.26
Current Volume	1386.7k
Average Volume	1088.9k

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income (1.74m TTM) > 0 and > 6% of Revenue (6% = 42.5m TTM)

FCFTA 0.04 (>2.0%) and ΔFCFTA -1.03pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 136.4% (prev 166.1%; Δ -29.73pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.04 (>3.0%) and CFO 130.9m > Net Income 1.74m (YES >=105%, WARN >=100%)

Net Debt (-59.9m) to EBITDA (157.2m) ratio: -0.38 <= 3.0 (WARN <= 3.5)

Current Ratio 8.36 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (56.5m) change vs 12m ago -0.74% (target <= -2.0% for YES)

Gross Margin 47.90% (prev 46.88%; Δ 1.01pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 24.60% (prev 21.76%; Δ 2.84pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 1.72 (EBITDA TTM 157.2m / Interest Expense TTM 44.3m) >= 6 (WARN >= 3)

Altman Z'' 3.39

(A) 0.33 = (Total Current Assets 1.10b - Total Current Liabilities 131.1m) / Total Assets 2.92b

(B) 0.15 = Retained Earnings (Balance) 443.0m / Total Assets 2.92b

(D) 0.52 = Book Value of Equity 439.4m / Total Liabilities 840.6m

Total Rating: 3.39 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 48.59

1. Piotroski 3.50pt = -1.50

2. FCF Yield 1.32% = 0.66

3. FCF Margin 14.91% = 3.73

4. Debt/Equity 0.33 = 2.45

5. Debt/Ebitda -0.38 = 2.50

6. ROIC - WACC (= -7.01)% = -8.77

7. RoE 0.09% = 0.01

8. Rev. Trend 18.39% = 1.38

9. EPS Trend -37.21% = -1.86

What is the price of RGEN shares?

As of November 13, 2025, the stock is trading at USD 158.01 with a total of 1,386,664 shares traded.
Over the past week, the price has changed by +8.34%, over one month by +6.28%, over three months by +30.16% and over the past year by +6.34%.

Is Repligen a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Repligen (NASDAQ:RGEN) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 48.59 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of RGEN is around 147.92 USD . This means that RGEN is currently overvalued and has a potential downside of -6.39%.

Is RGEN a buy, sell or hold?

Repligen has received a consensus analysts rating of 4.26. Therefore, it is recommended to buy RGEN.

Strong Buy: 10
Buy: 4
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the RGEN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	187	18.3%
Analysts Target Price	187	18.3%
ValueRay Target Price	166.6	5.4%

RGEN Fundamental Data Overview November 11, 2025

Market Cap USD = 8.04b (8.04b USD * 1.0 USD.USD)
P/E Trailing = 14282.001
P/E Forward = 74.0741
P/S = 11.3569
P/B = 3.9628
P/EG = 2.59
Beta = 1.128
Revenue TTM = 707.9m USD
EBIT TTM = 76.5m USD
EBITDA TTM = 157.2m USD
Long Term Debt = 525.6m USD (from longTermDebt, last fiscal year)
Short Term Debt = 19.3m USD (from shortTermDebt, last quarter)
Debt = 688.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -59.9m USD (from netDebt column, last quarter)
Enterprise Value = 7.98b USD (8.04b + Debt 688.9m - CCE 748.7m)
Interest Coverage Ratio = 1.72 (Ebit TTM 76.5m / Interest Expense TTM 44.3m)
FCF Yield = 1.32% (FCF TTM 105.5m / Enterprise Value 7.98b)
FCF Margin = 14.91% (FCF TTM 105.5m / Revenue TTM 707.9m)
Net Margin = 0.25% (Net Income TTM 1.74m / Revenue TTM 707.9m)
Gross Margin = 47.90% ((Revenue TTM 707.9m - Cost of Revenue TTM 368.8m) / Revenue TTM)
Gross Margin QoQ = 47.74% (prev 45.20%)
Tobins Q-Ratio = 2.73 (Enterprise Value 7.98b / Total Assets 2.92b)
Interest Expense / Debt = 3.98% (Interest Expense 27.4m / Debt 688.9m)
Taxrate = 12.86% (2.20m / 17.1m)
NOPAT = 66.6m (EBIT 76.5m * (1 - 12.86%))
Current Ratio = 8.36 (Total Current Assets 1.10b / Total Current Liabilities 131.1m)
Debt / Equity = 0.33 (Debt 688.9m / totalStockholderEquity, last quarter 2.08b)
Debt / EBITDA = -0.38 (Net Debt -59.9m / EBITDA 157.2m)
Debt / FCF = -0.57 (Net Debt -59.9m / FCF TTM 105.5m)
Total Stockholder Equity = 2.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.06% (Net Income 1.74m / Total Assets 2.92b)
RoE = 0.09% (Net Income TTM 1.74m / Total Stockholder Equity 2.03b)
RoCE = 3.00% (EBIT 76.5m / Capital Employed (Equity 2.03b + L.T.Debt 525.6m))
RoIC = 2.63% (NOPAT 66.6m / Invested Capital 2.54b)
WACC = 9.64% (E(8.04b)/V(8.73b) * Re(10.17%) + D(688.9m)/V(8.73b) * Rd(3.98%) * (1-Tc(0.13)))
Discount Rate = 10.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.63%
[DCF Debug] Terminal Value 74.84% ; FCFE base≈115.8m ; Y1≈142.9m ; Y5≈243.8m
Fair Price DCF = 51.22 (DCF Value 2.88b / Shares Outstanding 56.3m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -37.21 | EPS CAGR: -13.25% | SUE: 0.37 | # QB: 0
Revenue Correlation: 18.39 | Revenue CAGR: 0.40% | SUE: 2.59 | # QB: 3

Additional Sources for RGEN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle